|
Intervention
|
Control
| |
---|
Clinical topic
|
N
|
Mean before (sd)
|
Mean after (sd)
|
n
|
Mean before (sd)
|
Mean after (sd)
|
Ba (95% CI)
|
icc
|
Direction
|
p
|
---|
Anaemia
|
Iron preparations. oral
|
35
|
29.5 (22.5)
|
38.7 (25.6)
|
53
|
26.6 (27.6)
|
46.9 (54.2)
|
18.9 (−3.9, 41.7)
|
0.43
|
=
|
0.098
|
Urinary tract infections
|
Antibiotics UTI
|
8
|
40.8 (24.0)
|
44.5 (29.7)
|
80
|
46.5 (36.3)
|
55.3 (44.8)
|
6.3 (−21.1, 33.8)
|
0.33
|
↓
|
0.623
|
Prostate complaints
|
26
|
68.5 (47.0)
|
79.5 (63.0)
|
62
|
65.5 (53.6)
|
125.9 (91.9)
|
28.5 (6.5, 50.7)
|
0.27
|
↓
|
0.016
|
Alpha receptor blockers
|
26
|
57.5 (41.1)
|
66.5 (54.2)
|
62
|
54.0 (44.9)
|
101.5 (73.2)
|
44.2 (6.0, 82.3)
|
0.49
|
↓
|
0.027
|
5 alpha reductase inhibitors
|
26
|
11.0 (7.5)
|
13.0 (11.7)
|
62
|
11.5 (11.0)
|
24.5 (22.9)
|
11.1 (2.1, 20.2)
|
0.05
|
↓
|
0.020
|
Stomach complaints
|
28
|
455.1 (294.7)
|
565.2 (303.7)
|
60
|
275.7 (253.8)
|
509.1 (433.0)
|
61.1 (15.0, 107.2)
|
0.11
|
↓
|
0.014 b
|
H2 antagonists
|
28
|
28.0 (22.4)
|
32.4 (26.8)
|
60
|
23.2 (22.35)
|
24.2 (22.6)
|
−2.4 (−21.5, 16.7)
|
0.68
|
↑
|
0.788
|
Proton pump inhibitors
|
28
|
425.9 (276.1)
|
531.5 (283.8)
|
60
|
251.6 (234.0)
|
483.7 (414.7)
|
254.8 (60.1, 449.5)
|
0.66
|
↓
|
0.014 b
|
Misoprostol
|
28
|
0 (0)
|
0 (0)
|
60
|
0.1 (0.4)
|
0.1 (0.45)
|
0.1 (−0.1, 0.2)
|
0.01
|
↓
|
0.365
|
Triple therapy (ATC A02BD04)
|
28
|
1.2 (2.5)
|
1.4 (1.8)
|
60
|
0.9 (1.2)
|
1.1 (1.6)
|
0.1 (−0.7, 0.8)
|
0.20
|
↓
|
0.878b
|
Thyroid dysfunction
|
29
|
82.2 (45.9)
|
99.2 (57.5)
|
59
|
86.0 (63.1)
|
128.5 (94.6)
|
12.6 (0.7, 24.4)
|
0.08
|
=
|
0.040
|
Thyroid hormones
|
29
|
76.7 (43.5)
|
91.1 (52.2)
|
59
|
79.5 (58.8)
|
118.3 (87.8)
|
25.2 (2.1, 48.3)
|
0.19
|
=
|
0.035
|
Antithyroid preparations
|
29
|
5.5 (7.4)
|
8.2 (13.2)
|
59
|
6.5 (7.7)
|
10.1 (14.0)
|
0.2 (−4.2, 4.6)
|
0.11
|
↑
|
0.927
|
Perimenopausal complaints
|
24
|
59.4 (31.9)
|
56.5 (25.9)
|
64
|
51.2 (40.0)
|
51.3 (40.0)
|
1.5 (−2.3, 5.4)
|
0.21
|
↓
|
0.414
|
Oestrogens. oral
|
24
|
11.5 (8.0)
|
9.7 (6.2)
|
64
|
14.0 (14.0)
|
12.3 (12.4)
|
1.0 (−3.6, 5.5)
|
0.03
|
↓
|
0.612
|
Contraceptives (>50y)
|
24
|
5.1 (2.8)
|
5.9 (2.7)
|
64
|
3.2 (3.6)
|
6.5 (5.1)
|
2.5 (−0.9, 5.8)
|
0.31
|
↓
|
0.137
|
Hormone replacement therapy
|
24
|
38.7 (24.2)
|
36.3 (21.0)
|
64
|
31.1 (24.4)
|
29.8 (24.4)
|
2.6 (−9.7, 14.9)
|
0.60
|
↓
|
0.652
|
Clonidine
|
24
|
0.6 (1.5)
|
0.7 (2.7)
|
64
|
0.4 (1.5)
|
0.4 (1.6)
|
−0.3 (−1.4, 0.7)
|
0.11
|
↓
|
0.508 b
|
Tibolon
|
24
|
3.6 (3.7)
|
3.8 (4.1)
|
64
|
2.6 (3.0)
|
2.3 (3.3)
|
−0.7 (−2.0, 0.6)
|
0.00
|
↓
|
0.294 b
|
- The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
-
n = number of practices
-
aAdjusted difference between groups at end of intervention, corrected for baseline
-
bStatistically significant interaction
- Thyroid dysfunctioning: Clonidine
- P10: B (95% CI): 30.3 (15.1, 45.5). p: <0.001 P10: B (95% CI): 0.4 (−0.4, 1.2). p: 0.327
- P90: B (95% CI): 186.7 (88.7, 284.7). p: <0.001 P90: B (95% CI):−1.3 (−2.2,−0.4). p: 0.005
- Stomach complaints: Tibolon
- P10: B (95% CI): 1.4 (−39.6, 42.6). p: 0.937 P10: B (95% CI): 0.9 (−0.8, 2.6). p: 0.297
- P90: B (95% CI): 408.8 (341.1, 476.5). p: <0.001 P90: B (95% CI):−2.3 (−4.0,−0.6). p: 0.008
- PPIs: Triple therapy (ATC A02BD04)
- P10: B (95% CI): 91.5 (−120.0, 303.0). p: 0.378 P10: B (95% CI):−0.8 (−1.9, 0.3). p: 0.133
- P90: B (95% CI): 347.4 (159.2, 0.8). p: <0.001 P90: B (95% CI): 1.4 (0.3, 2.5). p: 0.014